2025-08-03 - Analysis Report
Okay, here's a report analyzing Transmedics Group Inc. (TMDX) based on the provided data.

## TMDX (Transmedics Group Inc.) Analysis

**Company Overview:** Transmedics Group Inc. is a medical technology company pioneering a novel approach to organ transplant therapy.

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 234.29%
*   **VOO Cumulative Return:** 65.71%
*   **Outperformance (Spread):**
    *   Current: 161.6
    *   Range: Max 293.6, Min -66.0
    *   Relative Spread: 63.3

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO).  The relative spread of 63.3 indicates that the current outperformance is in the upper half of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha    | Beta | Cap(B) |
|------------|----------|-------|----------|------|--------|
| 2019-2021  | -4.0%    | 63.4% | -52.0%   | 0.0  | 0.7    |
| 2020-2022  | 140.0%   | 68.3% | 138.0%   | 0.1  | 2.1    |
| 2021-2023  | 95.0%    | 69.4% | 77.0%    | 0.2  | 2.7    |
| 2022-2024  | 147.0%   | 82.8% | 121.0%   | 0.2  | 2.1    |
| 2023-2025  | 115.0%   | 82.8% | 69.0%    | 0.5  | 4.1    |

**Analysis:**

*   **CAGR:** Shows very high annual growth rates for most periods, but a negative CAGR for 2019-2021.
*   **MDD:** Maximum Drawdown is consistently high, indicating significant price volatility and risk.
*   **Alpha:** Strong positive alpha in most periods indicates outperformance relative to the benchmark, meaning returns beyond what would be expected based on the market's movement. The negative alpha for 2019-2021 suggests underperformance during that time.
*   **Beta:** The beta values are generally low, but have shown an increase, suggesting that the stock is becoming more sensitive to market movements.
*   **Market Cap:** The market capitalization has increased significantly over the period, indicating growth in the company's valuation.

### 2. Recent Price Action

*   **Current Price:** $120.55
*   **Previous Close:** $118.97
*   **Change:** $1.33
*   **5-day Moving Average:** 111.458
*   **20-day Moving Average:** 113.7052
*   **60-day Moving Average:** 122.8673

**Analysis:** The current price is above both the 5-day and 20-day moving averages, suggesting short-term upward momentum. However, it is slightly below the 60-day moving average, indicating potential resistance. The recent price increase of $1.33, though positive, isn't exceptionally large enough to indicate a major volatility event on its own, but should be considered in conjunction with other indicators.

### 3. Technical Indicators and Outlook

*   **Market Risk Indicator (MRI):** 0.3358 (Low Risk)
*   **RSI:** 54.25 (Neutral)
*   **PPO:** 0.9872 (Positive Momentum)
*   **Hybrid Signal:** cash_3%_Buy 80% of cash (252 shares - Caution - MRI:0.34) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 3% on 2025-08-01)
*   **Recent (20-day) Relative Spread Change:** 2.5 (+)  (Short-term Increase)
*   **Expected Return (%):** 56.1 (Long-Term, vs. S&P 500)

**Analysis:**

*   The **MRI** indicates low market risk.
*   The **RSI** is near neutral, suggesting the stock is neither overbought nor oversold.
*   The **PPO** indicates positive momentum.
*   The **Hybrid Signal** suggests a buy recommendation but with caution, indicating to allocate 80% of cash to purchase 252 shares while maintaining a 3% cash ratio.
*   The positive change in the relative spread over the last 20 days suggests increasing outperformance in the short term.
*   The high expected return of 56.1% suggests significant potential for long-term outperformance compared to the S&P 500.

### 4. Recent News & Significant Events

*   **[2025-07-31]:**  Major business developments, regulatory changes, or market events.
*   **[2025-08-02]:**  Analysts discussing performance in context of industry and global factors.
*   **[2025-07-30]:**  Notable stock volatility influenced by recent news, earnings, or executive actions.
*   **[2025-08-01]:**  Market experts highlighting risks and opportunities, advising investors to monitor news.

**Analysis:** The recent news suggests potential catalysts for both positive and negative price movements. Volatility and potential regulatory changes should be monitored closely.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** Transmedics has consistently beaten EPS expectations in recent quarters, which is a positive sign of strong performance and effective management. The significant beat in the most recent quarter (2025-07-30) could be a strong positive catalyst for the stock.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.16B   | 61.38%        |
| 2025-03-31 | $0.14B   | 61.47%        |
| 2024-12-31 | $0.12B   | 59.21%        |
| 2024-09-30 | $0.11B   | 55.94%        |
| 2024-06-30 | $0.11B   | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE    |
|------------|----------|--------|
| 2025-06-30 | $0.32B   | 10.97% |
| 2025-03-31 | $0.27B   | 9.64%  |
| 2024-12-31 | $0.23B   | 3.00%  |
| 2024-09-30 | $0.21B   | 2.01%  |
| 2024-06-30 | $0.19B   | 6.42%  |

**Analysis:**

*   **Revenue:** Revenue has been steadily increasing, indicating growth in sales.
*   **Profit Margin:** The profit margin is consistently high, indicating efficient operations and strong pricing power.
*   **Equity:** Equity has been increasing, suggesting that the company is building its asset base.
*   **ROE:** Return on Equity (ROE) shows profitability relative to equity. The increasing trend, especially in the most recent quarters, is a positive sign of efficient capital utilization.

### 7. Overall Assessment

Transmedics Group Inc. (TMDX) presents a compelling investment case. The company has significantly outperformed the S&P 500, demonstrating strong growth and profitability.  Recent earnings beats, increasing revenue, and high profit margins further support a positive outlook. However, high MDD numbers indicate significant price volatility and risk. Recent news suggests potential volatility, and investors should monitor company announcements and industry developments closely. The Hybrid Signal is cautiously optimistic.
